Cytek Biosciences to participate at the Singular Research's Las Vegas Invitational Conference

FREMONT, Calif., June 10, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced that the company will be participating in the upcoming Singular Research's Las Vegas Invitational Conference taking place June 14-16, 2026.

GlobeNewsWire • Jun 10, 2026

Cytek Biosciences to Unveil Next-Generation Spectral Flow Cytometry Innovations at CYTO 2026

At CYTO 2026, Cytek will showcase its cell analysis solutions, including the public debut of a new 7-laser Cytek Borealis full spectrum flow cytometer.

GlobeNewsWire • Jun 2, 2026

Cytek Biosciences, Inc. (CTKB) Q1 2026 Earnings Call Transcript

Cytek Biosciences, Inc. (CTKB) Q1 2026 Earnings Call Transcript

Seeking Alpha • May 8, 2026

Cytek Biosciences Reports First Quarter 2026 Financial Results

FREMONT, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the first quarter ended March 31, 2026.

GlobeNewsWire • May 7, 2026

Cytek Biosciences, Inc. (CTKB) Reports Q1 Loss, Beats Revenue Estimates

Cytek Biosciences, Inc. (CTKB) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to a loss of $0.09 per share a year ago.

Zacks Investment Research • May 8, 2026

Cytek Biosciences to Report First Quarter 2026 Financial Results on May 7, 2026

FREMONT, Calif., April 23, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced that it will report financial results for the first quarter 2026 after market close on Thursday, May 7, 2026.

GlobeNewsWire • Apr 23, 2026

Cytek® Biosciences Celebrates One Year of Operations at Singapore Facility, Accelerating Growth and Regional Impact

Cytek Biosciences celebrates one year of operations at its Singapore facility, which has enhanced Cytek's manufacturing capacity and regional service.

GlobeNewsWire • Mar 9, 2026

Cytek Biosciences, Inc. (CTKB) Q4 2025 Earnings Call Transcript

Cytek Biosciences, Inc. (CTKB) Q4 2025 Earnings Call Transcript

Seeking Alpha • Feb 27, 2026

Cytek Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results  and Provides 2026 Outlook

FREMONT, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the fourth quarter and year ended December 31, 2025.

GlobeNewsWire • Feb 26, 2026

Cytek Biosciences, Inc. (CTKB) Reports Q4 Loss, Tops Revenue Estimates

Cytek Biosciences, Inc. (CTKB) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of $0.02. This compares to earnings of $0.07 per share a year ago.

Zacks Investment Research • Feb 27, 2026